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Abstract
Background: Obesity has reached epidemic proportions in the United States. It is implicated in the development
of a variety of chronic disease states and is associated with increased levels of inflammation and oxidative stress.
The objective of this study is to examine the effect of Medifast’s meal replacement program (MD) on body weight,
body composition, and biomarkers of inflammation and oxidative stress among obese individuals following a
period of weight loss and weight maintenance compared to a an isocaloric, food-based diet (FB).
Methods: This 40-week randomized, controlled clinical trial included 90 obese adults with a body mass index (BMI)
between 30 and 50 kg/m
2, randomly assigned to one of two weight loss programs for 16 weeks and then
followed for a 24-week period of weight maintenance. The dietary interventions consisted of Medifast’s meal
replacement program for weight loss and weight maintenance, or a self-selected, isocaloric, food-based meal plan.
Results: Weight loss at 16 weeks was significantly better in the Medifast group (MD) versus the food-based group
(FB) (12.3% vs. 6.9%), and while significantly more weight was regained during weight maintenance on MD versus
FB, overall greater weight loss was achieved on MD versus FB. Significantly more of the MD participants lost ≥ 5%
of their initial weight at week 16 (93% vs. 55%) and week 40 (62% vs. 30%). There was no difference in satiety
observed between the two groups during the weight loss phase. Significant improvements in body composition
were also observed in MD participants compared to FB at week 16 and week 40. At week 40, both groups
experienced improvements in biochemical outcomes and other clinical indicators.
Conclusions: Our data suggest that the meal replacement diet plan evaluated was an effective strategy for
producing robust initial weight loss and for achieving improvements in a number of health-related parameters
during weight maintenance, including inflammation and oxidative stress, two key factors more recently shown to
underlie our most common chronic diseases.
Trial Registration: ClinicalTrials.gov NCT01011491
Background
Obesity is a chronic, complex, multifactorial disorder [1]
that has reached epidemic proportions in the United
States. Currently, an estimated 66% of the population is
categorized as overweight or obese, and 32.2% obese [2].
Obesity is associated with an increased risk of morbidity
and mortality secondary to complicating conditions that
include heart disease, diabetes, cancer, asthma, sleep
apnea, arthritis, reproductive complications, and psycho-
logical disturbances [3]. Moreover, obesity is associated
with greater degrees of inflammation and oxidative
stress [4], which have recently been shown to underlie
many chronic conditions, from cardiovascular disease
and cancer [5], to metabolic syndrome and nonalcoholic
fatty liver disease [6], to neurodegenerative diseases, like
Parkinson’s disease [7]. Given the prevalence of obesity, * Correspondence: ldavis@choosemedifast.com
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of effective treatment options, meal replacement diet
plans represent a viable strategy for controlling weight
and positively impacting health outcomes.
Results of our previous research [8] as well as that of
others [9] demonstrate the safety and efficacy of meal
replacements for weight loss and weight maintenance
among overweight and obese individuals. Evidence has
shown that dietary interventions utilizing meal replace-
ments result in greater weight loss [9] better compliance
[8,10], are more likely to ensure adequate intake of
essential nutrients [10,11], and demonstrate higher satis-
faction and lower drop-out rates compared to other
diets [8,9,11,12].
Previous studies have also found improvements in bio-
chemical markers over both the short-term (3-months)
and the long-term (≥ 27 months) [13-15] when meal
replacements were used as part of a hypocaloric diet.
More recently, meal replacement diet plans have been
shown to improve levels of C-reactive protein, a biomar-
ker of systemic inflammation [16,17]. Increased body
weight, percent body fat, and waist circumference have
been positively correlated with levels of C-reactive pro-
tein [18]. Individuals categorized as overweight (BMI:
25-29 kg/m
2) have been shown to have higher levels of
CRP compared to lean individuals BMI (<25 kg/m
2)
[19]. Elevated levels of CRP are associated with an
increased risk for insulin resistance, endothelial dysfunc-
tion [20], oxidative stress [21], and cardiovascular events
[22]. Calorie-restricted weight loss has been shown to
decrease CRP concentrations [16,17,22]. The loss of
body weight, particularly around the abdomen, may
lower the risk of chronic diseases like cardiovascular dis-
ease by dampening systemic inflammation [4,5] and
reducing levels of oxidative stress [23].
Thus, several lines of evidence suggest that hypocalo-
ric meal replacement diet plans may be an effective
strategy for fostering weight loss, ensuring compliance,
and improving health outcomes in today’s obesigenic
environment. We therefore sought to evaluate the
impact of a previously untested portion-controlled meal
replacement diet plan on body weight and body compo-
sition compared to an isocaloric, food-based diet plan
during a 16-week period of weight loss and 24-week
period of weight maintenance. Given the scarcity of
existing research evaluating the impact of meal replace-
ments on inflammation and oxidative stress, these bio-
markers were also collected as secondary outcomes.
Methods
Data Collection Procedures
All participants gave written informed consent, and the
protocol was approved by the Western Institutional
Review Board.
Participants were obese (BMI > 30.0 kg/m
2 ≤ 50.0
kg/m
2) men and women aged 18-65 who were inter-
e s t e di nw e i g h tl o s s ,b u tn o ta c t i v e l yi n v o l v e di na
weight loss program or losing weight. Some Medifast
meal replacements contain soy, wheat, gluten and nuts
so we ensured participants had no known allergies to
these ingredients. To avoid the potential affects on cal-
orie intake and compliance, participants consumed ≤
14 alcoholic beverages per week and agreed to avoid
alcohol intake during the study. Participants were not
currently using appetite-affecting medications [e.g
selective serotonin reuptake inhibitors (SSRIs), steroids,
Ritalin], and were not pregnant or lactating. Partici-
pants were required to have a normal electrocardio-
gram (EKG) and lab work within the past year as well
as the permission of their primary care provider to
enroll in the study. Subjects were recruited using
flyers, newspaper advertisements, and Craigslist.
Exclusion criteria included individuals that were
actively dieting; had chronic uncontrolled health pro-
blems (not including obesity or diabetes); had a pace-
maker or other internal electronic medical device;
reported schizophrenia, history of bipolar disorder, or a
current Major Depressive Disorder; dependence on alco-
hol or sedative-hypnotic drugs (e.g. benzodiazepines);
cognitive impairment severe enough to preclude
informed consent; or who were currently taking weight
loss or appetite affecting medications. Major eating dis-
orders were screened using the Eating Attitudes Test
(EAT). A score of > 30 was exclusionary.
Individuals meeting initial eligibility criteria by phone
were invited for in-person screening at a suburban Balti-
more clinical research facility. At this visit, written
informed consent and Health Insurance Portability and
Accountability Act (HIPAA) authorization were
obtained. Measurements of height, weight, waist circum-
ference (WC), blood pressure, pulse, and body composi-
tion using bioelectrical impedance (BIA) were collected.
The EAT screening tool was administered. Data on gen-
eral demographics, medical history, weight history, alco-
hol and cigarette use, exercise, eating habits, and
sources of stress were collected.
One hundred fifteen obese adults met initial eligibility
criteria and attended the in-person screening. Six indivi-
duals withdrew immediately following screening, 2 indi-
viduals were excluded during the in-person screening
visit, and 17 individuals failed to attend the baseline
visit resulting in a final sample of 90 participants
(64 women, 26 men).
Intervention
Participants were randomly assigned to follow one of
two hypocaloric (providing less than estimated calorie
n e e d sa sd e t e r m i n e db yt h eM i f f l i n - S t .J e o re q u a t i o n )
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Medifast 5 & 1 Plan (MD) (Medifast, Inc, Owings
Mills, MD) utilizing portion-controlled meal replace-
ments or an isocaloric food-based plan (FB) using
guidelines from the USDA Food Guide Pyramid, both
providing ~1000 kilocalories (kcal) per day. At the
baseline visit, a registered dietitian reviewed the dietary
intervention each participant was randomized to.
Members of the study staff and study participants were
not able be blinded to the type of diet, though partici-
pants received identical interventions and staff atten-
tion. After the initial 16-week weight loss phase both
groups entered a 24-week long maintenance phase (for
a total of 40 weeks), gradually increasing calorie intake
to a maintenance energy level. The MD group contin-
ued to utilize meal replacements during the weight
maintenance phase.
The intervention diet plan (Medifast 5&1 plan)
included 5 meal replacements (90-110 kcal/each), 5-7 oz
lean protein, 1 1/2 cups of non-starchy vegetables, and
up to 2 fat servings daily (providing 800-1000 kcal). The
meal replacements used in this study were low fat, low
glycemic index (GI), low sugar, provided a balanced ratio
of carbohydrates to proteins, and were either soy and/or
whey protein based. The FB plan included 3 ounces of
grains, 1 cup of vegetables, 1 cup of fruit, 2 cups of milk,
5-7 ounces of lean protein, and 3 teaspoons of fat daily
(providing ~1000 kcal/day). The FB group was also
instructed to take a multivitamin and additional calcium
to ensure micronutrient needs were met while following
a low-calorie meal plan. Vitamin and mineral fortification
of the Medifast meals precluded the need for additional
supplementation in the MD group.
The Mifflin-St. Jeor equation was used to estimate
total daily energy requirements and develop individua-
lized meal plans during the 24-week weight maintenance
phase. The FB group followed meal plans based on
USDA Food Guide Pyramid guidelines and their esti-
mated energy needs while the MD group was provided
a maintenance meal plan incorporating 3-5 meal repla-
cements, depending on the daily energy requirement of
the individual. Maintenance phase meal plans were
reviewed with each participant by a registered dietitian
prior to the beginning of the maintenance phase.
Physical activity above normal daily activities was not
a requirement for participation in the study. While fol-
lowing the 5 & 1 plan, 45 minutes of exercise per day
above normal daily activities, is the recommended maxi-
mum. This same guideline was recommended to the FB
group during the weight loss phase. No specific guide-
lines for physical activity were provided during the
weight maintenance phase of the study.
Each participant met with a dietitian bi-weekly during
the 16-week weight loss phase for dietary and behavioral
counseling and at 12 week intervals during the 24 week
weight maintenance phase (weeks 28 and 40 of the
study, respectively). Five different dietitians were used to
counsel subjects. Each dietitian had subjects from both
groups and reviewed identical information with each
subject. Every effort was made to have the subjects see
the same dietitian throughout the study; however, it was
made clear at screening and throughout the study that
an alternate dietitian could be requested for any reason
until a suitable match was found. At each visit, all parti-
cipants were provided a self-study module focusing on a
behavioral component of weight loss (e.g. stress
management).
Participants in the MD group received 40 weeks of
meal replacements (16 week supply for weight loss and
24 week supply for weight maintenance) free of cost.
After the study was completed, the FB group had the
option of receiving an equivalent amount of meal repla-
cements free of cost or a cash payment of $375.
Measurements
Baseline measures for weight, blood pressure, waist cir-
cumference (WC), and body composition [percent body
fat, lean muscle mass (LMM) and visceral fat rating
(VFR)] were obtained. Bioelectrical impedance (BIA)
was used to determine body composition using Tanita’s
Iron Man BC-549 scale. VFR was determined by an
algorithm based on BIA results that generates a rating -
the amount of visceral fat itself is not measured. The
range for the VFR is 0-59 with a healthy level of visceral
fat receiving a rating of 0-12 and an excess level of visc-
eral fat receiving a rating of 13-59. Weight and blood
pressure were measured bi-weekly during the 16-week
weight loss phase and at 12 week intervals during the
maintenance phase (weeks 28 and 40 of the study,
respectively). WC, pulse, and body composition were
measured at weeks 4, 8, 12, 16, 28 and 40.
A lipid panel, C-reactive protein (CRP), and urine lipid
peroxides (ULP) were measured at baseline, at the end
of the weight loss phase (week 16) and at the end of
weight maintenance (week 40). CRP was used as a bio-
marker of inflammation and ULP was used as a biomar-
ker of oxidative stress. Lipid panels and CRPs were
drawn at a LabCorp patient services center of the parti-
cipant’s choice http://www.labcorp.com. Low levels of
CRP were defined as ≤ 3.0 mg/dL and high were defined
as > 3.0 mg/dL, which is above the upper limit of nor-
mal for LabCorp. Urine samples were collected and sent
to Genova Diagnostics http://www.gdx.net for analysis.
Satiety (post-meal fullness and general fullness) was
assessed using a 100 mm visual analog scale (VAS)
anchored by extremes of fullness. Participants rated
their level of fullness over the previous 2 weeks, at base-
line and week 16.
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To have a 90 percent chance of detecting a 2% differ-
ence between the two diet groups in percentage of
initial body weight lost at 16 weeks, with an assumed
standard deviation of 5% and a noncompletion rate of
30%, 90 participants were required to be randomized
(2 sided, a = .05) to one of the two groups.
Between group differences in demographic, anthropo-
metric and biochemical variables were investigated using
c
2for categorical variables and non-parametric tests for
continuous variables (e.g., Mann-Whitney U). Non-para-
metric tests were used due to the non-normal distribu-
tion of the sample’s data for most outcome variables. To
examine bivariate longitudinal changes, Wilcoxon
signed-rank tests were employed. Random effects logis-
tic regression models were used to examine the associa-
tion between diet group and outcome variables (i.e.,
anthropometric and biochemical indices while control-
ling for confounding variables). Random effects regres-
sion allows for a subject-specific interpretation, and
adjustment for excess between-individual heterogeneity.
Where results did not differ between bivariate t-tests
and random effects analyses, only t-test results are
shown. Significance was defined as p < 0.05. Analyses
were conducted using SPSS Version 15 [24] and Stata
Version 10 [25].
Results
Subjects
Of the 90 eligible participants (MD = 45, FB = 45) who
began the diet, 48 (53%) completed the 16-week active
weight loss phase. These included 28 of 45 (62.2%) ran-
domized to the MD group and 20 of 45 (55.6%) rando-
mized to the FB group (c
2 =2 . 8 5 7 ,d f=1 ,p=0 . 0 9 1 ) .
At week 40, after completion of 24 weeks of weight
maintenance, 46 participants remained in the study, 26
MD (57.8%) and 20 FB (55.6%) (c
2 =1 . 6 0 1 ,d f=1 ,p=
0.206). MD had significantly higher baseline urine ULPs
than FB group (p = 0.05), otherwise there were no sig-
nificant differences at baseline in other outcome mea-
sures. There were no significant adverse events in either
group. Baseline characteristics are shown in Table 1.
Results are shown (Tables 2, 3, 4, 5) for completers at
each stage (post 16-week weight loss, post 24-weeks
maintenance phase (week 40)).
Weight
After the 16-week active weight loss phase, weight loss
among completers averaged 12.3% (13.5 ± 5.9 kg) on
the MD versus 6.7% (6.5 ± 6.8 kg) on the FB (p =
0.001). Twenty-six of 28 (92.9%) MD participants, lost ≥
5% of their initial body weight at 16 weeks, versus 11 of
20 (55.0%) FB participants (c
2 = 9.47, df = 1, p = 0.002).
21 of 28 (75%) MD participants lost ≥ 10%, versus 5 of
20 (25%) FB participants (c
2 = 11.75, df = 1, p = 0.001).
Over the16 weeks of active weight loss, BMI reduced
from 38.5 to 33.8 kg/m
2, an average decrease of 12.3%
for the MD, and from 37.8 to 34.7 kg/m
2,a na v e r a g e
decrease of 6.7% for FB participants, representing a sig-
nificant between group difference (Mann-Whitney U =
125, Z = -3.24, p = 0.001) (Table 2).
At week 40, after 24 weeks of weight maintenance, the
MD group regained 4.8 ± 5.8 kg (Z = -3.565, p <
0.0001) of initial weight loss compared to the FB group
that regained 0.8 ± 4.8 kg (Z = -0.728, p = 0.467); this
was a significant between group difference (Mann
Whitney U = 153, Z = -2.216, p = 0.027). However,
both groups maintained significant weight loss (from
baseline to week 40) with a mean net loss of 8.9 ± 8.9
kg (-7.8%; Z = -3.76, p < 0.0001) in the MD group and
5.7 ± 8.6 kg (-5.9%; Z = -2.86, p = 0.004) in the FB
group. Significantly more participants in the MD group,
16 of 26 (61.5%), maintained ≥ 5% weight loss compared
to only 6 of 20 (30%) in the FB group (c
2 = 4.506, df =
1, p = 0.034). 10 of 26 (38.5%) MD participants main-
tained a ≥ 10% weight loss, versus 4 of 20 (20%) FB par-
ticipants (c
2 = 1.82, df = 1, p = 0.117). At week 40, BMI
in the MD group remained reduced from baseline by
7.8% versus 5.9% in the FB group (Mann-Whitney U =
195, Z-1.44, p = 0.15) (Table 2).
Body Fat Percentage and Lean Muscle Mass
During the 16-week weight loss phase, body fat %
among the MD group decreased by a mean of 5.6%,
representing a 13.6% reduction from baseline (Z = -454,
p < 0.0001), whereas the FB group experienced a non-
signficant average decrease of 1.5%, representing a 2.7%
reduction from baseline (Z = -1.107, p = 0.27). The
between group difference for body fat % was statistically
significant (Mann-Whitney U = 102.5, Z = -3.605, p <
0.0001). Lean Muscle Mass as a percent of total weight
was significantly increased from baseline to Week 16 in
the MD group (from 54.1% to 59.3%; Z = -427, p <
0.0001), whereas the FB group did not experience any
Table 1 Baseline Characteristics
Demographics MD Group
(n = 45)
FB Group
(n = 45)
Between
Group p-value
Age (years) 43.0 ± 10.2 45.1 ± 11.6 P = 0.362
Gender Male 15 (66.7%) 11 (24.4%) P = 0.352
Female 30 (33.3%) 34 (75.6%)
Ethnicity Caucasian 27 (60.0%) 19 (42.2%) P = 0.224
African Am 16 (35.6%) 25 (55.6%)
Hispanic 1 (2.2%) 0 (0.0%)
Mixed 1 (2.2%) 1 (2.2%)
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was significant between groups (p < 0.0001) (Table 1).
At week 40, a mean body fat % decrease among the
MD group was 2.9%, whereas the FB group decreased
by 1.8% (p < 0.0001 and p = 0.10, respectively), repre-
senting a marginally significant between group differ-
ence (Mann Whitney U = 179, Z = -1.784, p = 0.07).
Again, lean muscle mass as a percent of total weight
was significantly increased by 4.5% from baseline to
week 40 in the MD group (Z = -2.74, p = 0.006),
whereas the FB group did not experience any significant
change (Z = -1.38, p = 0.17). This was not a significant
between group difference (p = 0.126) (Table 2).
Waist Circumference and Visceral Fat Rating
During the 16-week weight loss phase, WC decreased by
a mean of 13.0 cm (11.2%) in the MD group and 7.8 cm
(6.8%) in the FB group (p = 0.003 and p < 0.0001,
respectively). Visceral fat rating (VFR) was significantly
reduced in the MD group, from a mean of 13.8 ± 3.8 at
baseline to 10.6 ± 3.5 at 16 weeks, an average 25.4%
reduction (Z = 4.315, p < 0.0001), while the FB group
experienced an average marginal decrease of 3.7% (Z =
1.743, p = 0.081). This difference between group was
significant (Mann Whitney U = 79, Z = 3.948, p <
0.0001) (Table 1).
At week 40, WC in the MD group decreased by a
mean of 9.7 cm (8.4%) [p < 0.0001], compared to 3.8
cm (3.3%) [p = 0.12] of the FB group, representing a
significant difference between group (Mann Whitney
U = 125, Z = -2.23, p = 0.03). Both groups retained a
significant decrease in VFR from baseline. VFR in the
MD group decreased 14.7% (Z = 3.53, p < 0.0001),
whereas the FB group decreased by 9.2% (Z = -2.064,
p = 0.039) for a marginally significant between group
difference (Mann Whitney U = 171.5, Z = -1.637, p =
0.10) (Table 2).
Blood Pressure and Pulse
After the 16-week weight loss phase, both groups
experienced statistically significant declines in both sys-
tolic and diastolic blood pressure. The MD group low-
ered systolic blood pressure by a mean of 10.9 mmHg
(8.5%) versus 9.2 mmHg (7.1%) for the FB group
Table 2 Anthropometric Measures at Week 0 and Week 16
Measurement Week MD Group
Mean ± SD
Within Group
Δ p-value
Week FB Group
Mean ± SD
Within Group
Δ p-value
Between Group
Δ p-value
Weight (kgs)* 0 (n = 45) 111.6 ± 25.7 p < 0.0001 0 (n = 45) 104.1 ± 17.1 p < 0.0001 p = 0.001
16 (n = 28) 98.0 ± 23.9 16 (n = 20) 95.4 ± 18.9
BMI (kg/m2) 0 (n = 45) 38.5 ± 6.8 p < 0.0001 0 (n = 45) 37.8 ± 4.5 p = 0.001 p = 0.001
16 (n = 28) 33.8 ± 6.6 16 (n = 20) 34.7 ± 5.9
Waist 0 (n = 45) 116.6 ± 15.5 p < 0.0001 0 (n = 45) 114.2 ± 15.0 p = 0.003 p = 0.028
Circumference (cm) 16 (n = 26) 104.5 ± 16.9 16 (n = 20) 104.9 ± 14.9
Body Fat (%)* 0 (n = 45) 42.8 ± 7.7 p < 0.0001 0(n = 45) 44.1 ± 6.4 p = 0.268 p < 0.0001
16 (n = 27) 37.5 ± 8.8 16 (n = 20) 41.0 ± 7.6
Lean Muscle 0 (n = 41) 56.8 ± 11.4 p < 0.0001 0 (n = 41) 53.3 ± 8.7 p = 0.003 p = 0.56
Mass (kgs) 16 (n = 25) 55.0 ± 10.4 16 (n = 20) 52.8 ± 9.4
Visceral Fat 0 (n = 41) 13.8 ± 3.8 p < 0.0001 0 (n = 41) 13.7 ± 5.0 p = 0.081 p < 0.0001
Rating 16 (n = 25) 10.6 ± 3.5 16 (n = 20) 14.2 ± 6.1
Systolic BP 0 (n = 45) 125.4 ± 13.9 p < 0.0001 0 (n = 45) 125.8 ± 13.6 p = 0.003 p = 0.667
(mmHg) 16 (n = 28) 113.6 ± 14.3 16 (n = 20) 115.8 ± 12.3
Diastolic BP 0 (n = 45) 83.2 ± 9.5 p = 0.001 0 (n = 45) 82.6 ± 10.2 p = 0.016 p = 0.622
(mmHg) 16 (n = 28) 74.2 ± 8.8 16 (n = 20) 74.2 ± 6.8
Pulse, 0 (n = 45) 76.4 ± 9.3 p = 0.001 0 (n = 45) 73.9 ± 9.2 p = 0.011 p = 0.112
(bpm) 16 (n = 26) 67.2 ± 8.6 16 (n = 19) 71.2 ± 8.1
Δ = Change from baseline to 16 weeks.
* = Primary outcomes. All others are secondary outcomes.
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blood pressure, the MD group experienced a mean 6.5
mmHg (7.6%) decline, versus a 5.2 mmHg (5.7%) decline
for the FB group (p = 0.001 and p = 0.016, respectively).
Both groups had significant decreases in pulse; a 10.7%
reduction in the MD group (Z = -3.427, p = 0.001) and
a 5.7% reduction in the FB group (Z = -2.538, p =
0.011) (Table 2).
At week 40, the MD group reduced systolic blood
pressure by 6.0 mmHg (4.5%) and the FB group by 8.3
mmHg (6.5%) (p = 0.01 and p = 0.02, respectively). Dia-
stolic blood pressure was decreased by 5.5 mmHg
(6.2%) for the MD group, compared to 0.9 mmHg
(0.45%) in the FB group (p = 0.01 and p = 0.62, respec-
tively) for a statistically significant between group differ-
ence (Mann Whitney U = 173, Z = -1.93, p = 0.05).
Both groups retained significant decreases in pulse at
week 40. The MD group remained reduced by
7.9% (Z = -2.858, p = 0.004); the FB group by 4.5%
(Z = -2.24, p = 0.025). There was no significant differ-
ence between the groups (Table 3).
Satiety
There were no significant between group differences for
either question assessing satiety at week 16. There was
no difference in post-meal fullness (MD = 6.7 ± 2.0 vs.
FB = 5.7 ± 2.1, p = 0.203) or general fullness (MD = 5.8 ±
1. vs. FB = 5.2 ± 2.2, p = 0.405).
CRP
During the 16-week weight loss phase, CRP decreased in
the MD group by a mean of 1.9 mg/dL (7.8%), com-
pared to a 3.3 mg/dL (32.1%) decrease in the FB group
(p = 0.20 and p = 0.018, respectively), however, there
was no statistically significant between group differences
observed (Table 4).
At week 40, CRP levels in the MD group decreased by
a mean of 3.1 (40.7%), whereas the FB group decreased
by a mean of 4.1 (30.1%) (p < 0.0001 and p = 0.01,
respectively). There were no significant differences
between groups (Table 5).
Regression was used to further examine the relationship
between CRP levels at 40 weeks and predictor variables
Table 3 Anthropometric Measures at Week 0 and Week 40
Measurement Week MD Group
Mean ± SD
Within Group
Δ p-value
Week FB Group
Mean ± SD
Within Group
Δ p-value
Between Group
Δ p-value
Weight 0 (n = 45) 111.6 ± 25.7 p < 0.0001 0 (n = 45) 104.1 ± 17.1 p = 0.004 p = 0.18
(kgs)* 40 (n = 26) 103.6 ± 25.2 40 (n = 20) 96.2 ± 19.6
BMI 0 (n = 45) 38.5 ± 6.8 p < 0.0001 0 (n = 45) 37.8 ± 4.5 p = 0.003 p = 0.18
(kg/m2) 40 (n = 26) 35.6 ± 7.4 40 (n = 20) 35.0 ± 6.2
Waist 0 (n = 45) 116.6 ± 15.5 p < 0.0001 0 (n = 45) 114.2 ± 15.0 p = 0.121 p = 0.026
Circumference (cm) 40 (n = 25) 106.4 ± 17.3 40 (n = 17) 109.9 ± 15.4
Body Fat (%)* 0 (n = 45) 42.8 ± 7.7 p < 0.0001 0 (n = 45) 44.1 ± 6.4 p = 0.103 p = 0.074
40 (n = 26) 39.9 ± 8.1 40 (n = 20) 40.7 ± 9.1
Lean Muscle 0 (n = 41) 56.8 ± 11.4 p = 0.008 0 (n = 41) 53.3 ± 8.7 p = 0.009 p = 0.795
Mass (kg) 40 (n = 24) 55.0 ± 10.0 40 (n = 20) 53.2 ± 10.0
Visceral Fat 0 (n = 41) 13.8 ± 3.8 p < 0.0001 0 (n = 41) 13.7 ± 5.0 p = 0.039 p = 0.102
Rating 40 (n = 24) 12.0 ± 4.2 40 (n = 20) 13.7 ± 6.0
Systolic BP 0 (n = 45) 125.4 ± 13.9 p = 0.009 0 (n = 45) 125.8 ± 13.6 p = 0.016 p = 0.373
(mmHg) 40 (n = 26) 117.2 ± 13.7 40 (n = 20) 116.7 ± 14.8
Diastolic BP (mmHg) 0 (n = 45) 83.2 ± 9.5 p = 0.009 0 (n = 45) 82.6 ± 10.2 p = 0.618 p = 0.053
(mmHg) 40 (n = 26) 75.1 ± 10.6 40 (n = 20) 78.5 ± 9.2
Pulse 0 (n = 45) 76.4 ± 9.3 p = 0.004 0 (n = 45) 73.9 ± 9.2 p = 0.025 p = 0.324
(bpm) 40 (n = 26) 69.8 ± 8.4 40 (n = 20) 72.4 ± 6.8
Δ = Change from baseline to 40 weeks.
* = Primary outcomes. All others are secondary outcomes.
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Measurement
† Week MD Group
Mean ± SD
Within Group
Δ p-value
Week FB Group
Mean ± SD
Within Group
Δ p-value
Between Group
Δ p-value
Total Cholesterol 0 (n = 39) 191.2 ± 39.5 p = 0.841 0 (n = 40) 187.5 ± 43.0 p = 0.687 p = 0.409
(mg/dl) 16 (n = 25) 181.3 ± 40.4 16 (n = 20) 184.9 ± 45.9
HDL 0 (n = 39) 52.0 ± 16.0 p = 0.843 0 (n = 40) 51.8 ± 18.0 p = 0.261 p = 0.62
(mg/dl) 16 (n = 25) 51.6 ± 11.3 16 (n = 20) 48.2 ± 11.3
LDL 0 (n = 39) 117.3 ± 31.8 p = 0.253 0 (n = 40) 108.8 ± 32.0 p = 0.779 p = 0.396
(mg/dl) 16 (n = 25) 111.4 ± 34.4 16 (n = 19) 110.7 ± 37.6
VLDL 0 (n = 38) 21.9 ± 13.0 p = 0.026 0 (n = 37) 27.9 ± 17.9 p = 0.01 p = 0.652
(mg/dl) 16 (n = 24) 17.5 ± 9.8 16 (n = 20) 26.1 ± 16.4
Triglycerides 0 (n = 39) 109.2 ± 63.7 p = 0.061 0 (n = 40) 134.7 ± 86.8 p = 0.009 p = 0.502
(mg/dl) 16 (n = 25) 91.8 ± 52.7 16 (n = 20) 130.4 ± 81.6
CRP 0 (n = 38) 5.7 ± 4.8 p = 0.200 0 (n = 39) 7.1 ± 9.4 p = 0.018 p = 0.45
(mg/L) 16 (n = 25) 3.6 ± 2.9 16 (n = 20) 4.3 ± 4.7
ULP 0 (n = 44) 6.1 ± 2.2 p = 0.684 0 (n = 44) 5.5 ± 1.7 p = 0.538 p = 0.973
(micromol/g creatinine) 16 (n = 27) 6.2 ± 2.2 16 (n = 20) 5.3 ± 2.4
Δ = Change from baseline to 16 weeks.
† = Secondary outcomes.
Table 5 Lipid and Inflammatory Measures at Week 0 and Week 40
Measurement
† Week MD Group
Mean ± SD
Within Group
Δ p-value
Week FB Group
Mean ± SD
Within Group
Δ p-value
Between Group
Δ p-value
Total 0 (n = 39) 191.2 ± 39.5 p = 0.154 0 (n = 40) 187.5 ± 43.0 p = 0.003 p = 0.632
Cholesterol (mg/dl) 40 (n = 23) 182 ± 32.5 40 (n = 20) 183.0 ± 45
HDL 0 (n = 39) 52.0 ± 16.0 p = 0.509 0 (n = 40) 51.8 ± 18.0 p = 0.029 p = 0.86
(mg/dl) 40 (n = 23) 53.2 ± 12.2 40 (n = 20) 49.6 ± 11.8
LDL 0 (n = 39) 117.3 ± 31.8 p = 0.088 0 (n = 40) 108.8 ± 32.0 p = 0.099 p = 0.811
(mg/dl) 40 (n = 23) 107.1 ± 28.5 40 (n = 20) 104.1 ± 31.1
VLDL 0 (n = 38) 21.9 ± 13.0 p = 0.614 0 (n = 37) 27.9 ± 17.9 p = 0.38 p = 0.648
(mg/dl) 40 (n = 23) 21.7 ± 14.0 40 (n = 20) 29.3 ± 16.4
Triglycerides 0 (n = 39) 109.2 ± 63.7 p = 0.516 0 (n = 40) 134.7 ± 86.8 p = 0.391 p = 0.579
(mg/dl) 40 (n = 23) 107.7 ± 70.1 40 (n = 20) 137.4 ± 101.2
CRP 0 (n = 38) 5.7 ± 4.8 p < 0.0001 0 (n = 39) 7.1 ± 9.4 p = 0.008 p = 0.886
(mg/L) 40 (n = 23) 2.6 ± 2.2 40 (n = 20) 3.5 ± 3.6
ULP 0 (n = 44) 6.1 ± 2.2 p = 0.006 0 (n = 44) 5.5 ± 1.7 p = 0.837 p = 0.038
(micromol/g creatinine) 40 (n = 23) 4.9 ± 2.4 40 (n = 20) 5.4 ± 2.5
Δ = Change from baseline to 40 weeks.
† = Secondary outcomes.
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line CRP levels, intervention group and time was found
(p = 0.04), even when controlling for significant confoun-
ders (i.e., birth control use and changes in cholesterol).
A dichotomous variable was used to characterize baseline
CRP levels (low levels defined as ≤ 3.0 mg/dL; high was
defined as > 3.0 mg/dL). Both FB and MD groups with
low baseline CRP levels experienced no significant changes
over time. The FB group with high baseline CRP levels
experienced marginally significant decreases over time
(b =- 5 . 8 3 ,p=0 . 0 6 ) ;h o w e v e rt h eM Dg r o u pw i t hh i g h
baseline CRP levels was the only sub-group to experience
significant decreases over the 40 weeks (b = -5.03,
p<0 . 0 0 0 1 ) .
Urine Lipid Peroxides (ULP)
At 16 weeks, no significant within or between group dif-
ferences in ULP were seen. At week 40, ULP levels in
the MD group decreased a mean of 1.3 micromol/g
creatinine (17.5%), compared to 0.2 micromol/g creati-
nine (5.4%) among the FB group (p = 0.01 and p = 0.84,
respectively), which represented a significant difference
b e t w e e ng r o u p s( M a n nW h i t n e yU=1 4 5 ,Z=- 2 . 0 7 ,
p = 0.04) (Table 4).
Regression was also used to further examine the rela-
tionship between ULPs at 40 weeks with predictor vari-
ables and confounders. A significant interaction between
intervention group and time was found (p = 0.05), even
when controlling for significant confounders (i.e., age,
gender, positive report of arthritis, birth control use and
changes in cholesterol). The FB group did not experi-
ence any significant changes over the 40 weeks (b =
0.09, p = 0.84), whereas there was a significant mean
decrease over time in the MD group (b = -1.26, p =
0.005) (Table 5).
Cholesterol
At 16 weeks, both MD and FB groups nonsignificantly
lowered total cholesterol levels by a mean of 0.6 ± 15%
and 2.6 ± 16%, respectively. Similarly, neither group
experienced significant changes in low density lipopro-
tein (LDL) or high density lipoprotein (HDL) cholesterol
levels at 16 weeks. However, very low density lipopro-
tein (VLDL) levels were significantly decreased from
baseline, in both the MD (-8.8%; Z = -2.23, p = 0.03)
and FB groups (-15.3%; Z = -2.55, p = 0.01) (Table 4).
At week 40, only the FB group retained significant
reductions in total cholesterol (-3.6%; Z = -2.99, p =
0.003). HDL cholesterol remained significantly increased
in the FB group (up 6.1%, p = 0.03). Both groups
retained marginally significant reductions in LDL cho-
lesterol from baseline. MD group remained reduced by
4.4% (Z = -1.71, p = 0.09) and the FB group by 5.4% (Z
= 1.65, p = 0.10). No significant changes in VLDL
remained in either group. There were no significant
between group differences for total cholesterol, HDL,
LDL, or VLDL at week 40 (Table 5).
Triglycerides
After the initial 16-week weight loss phase, both groups
reduced fasting triglycerides; the MD group reduced tri-
glycerides by 4.6% (Z = -1.87, p = 0.06) and the FB
group by 15.3% (Z = 2.60, p = 0.01) (Table 4). At week
40, there were no significant differences from baseline
in either group. There were no significant between
group differences at either time point (Table 5).
Discussion
Increasingly, meal replacement diet plans have been
demonstrated to provide safe, effective, sustainable
weight loss, and have also been shown to yield signifi-
cant improvements in health outcomes [8,9,13-15].
Nutrient rich, portion-controlled meal replacements are
a strategic tool that may assist dieters as they navigate
the obesigenic environment by providing a convenient
alternative to over-sized, high fat, empty calorie choices
[23]. For these reasons, this study sought to evaluate the
impact of a portion-controlled meal replacement diet
plan on body weight and body composition compared
to an isocaloric, food-based diet plan for a 16-week per-
iod of weight loss and 24-week period of weight
maintenance.
Following a low-energy diet consisting of five, 90-110
kcal meal replacements daily and one self-prepared meal
(MD group) led to twice the weight loss at the end of 16-
weeks compared to a food group prescribed the same
number of calories based on food selection guidelines of
the USDA Food Guide Pyramid. Clinically significant
weight loss, as defined by the Institute of Medicine
(IOM), is a loss of at least 5% of starting body weight in
one year [26,27]; 93% of participants following the MD
diet compared to only 55% of the FB group achieved this
in a 10-month time period. Moreover, a robust mean
weight loss of 12.3% was observed among the MD group
after 16 weeks, a magnitude many drugs currently used
for obesity pharmacotherapy do not achieve [28].
While there was not a significant difference between
groups in absolute weight loss at 40 weeks, and weight
regain during maintenance was greater among the MD
group than it was for the FB group, clinically significant
weight loss was maintained by considerably more of the
MD group (61.5%), compared to the FB group (30%).
Overall, the MD group maintained a mean net loss from
baseline approximately 2% greater than the FB group
(-7.8% (-8.9 ± 8.9 kg) and -5.9% (-5.7 ± 8.5 kg)
respectively).
Significant improvements in body composition were
also observed in the MD group compared to the FB
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lost five times more body fat and seven times more visc-
eral fat, while maintaining more than twice the amount
of lean muscle mass. Maintenance of lean muscle mass
during weight loss on a hypocaloric diet is an important
difference between the meal replacement diet plan
under study and other weight loss plans [29]. Sustaining
lean muscle mass is a crucial mechanism for maintain-
ing weight loss, as muscle provides a higher contribution
to resting metabolic rate (RMR) than does fat [30-32]. A
likely explanation for the favorable body composition
changes observed in the MD group is the macronutrient
composition (low fat, low carbohydrate, higher protein)
of the meal replacements, which is difficult to achieve
without significant planning when dieters self-prepare
meals.
After 16 weeks of weight loss and another 24 weeks of
weight maintenance, both groups experienced improve-
ments in biochemical outcomes and other clinical indi-
cators of health, like blood pressure and pulse. At 40
weeks, significant differences in the magnitude of
improvement in biomarkers of cardiovascular health
emerged in the MD group compared to the FB group.
Significant improvements in diastolic blood pressure,
waist circumference, and oxidative stress were found
only in the MD group. Concentrations of CRP were also
significantly decreased from baseline in the MD group,
especially among those with high baseline CRP.
Mechanistically, decreases in total fat, visceral fat, and
waist circumference may be responsible for the
decreases seen in inflammation and oxidative stress, as
abdominal fat has been shown to produce inflammatory
molecules that underlie metabolic syndrome and cardio-
vascular disease [33]. This is highlighted by recent
research which found central obesity to be an indepen-
dent predictor of coronary heart disease and cardiovas-
cular disease deaths [34], and waist circumference alone
as a very good predictor of health risk and mortality in
overweight and obese individuals [35,36].
A possible factor contributing to the greater overall
effectiveness for initial weight loss on the meal replace-
ment diet plan studied is ease of use for the end-user,
leading to enhanced compliance with the diet plan. Bet-
ter adherence to the diet using meal replacements has
been shown over both the short-term and long-term
[8,9] as well as among subgroups of individuals, such as
those with type 2 diabetes, who are often challenging in
terms of compliance and achievement of weight loss [8].
While not statistically significant, this was demonstrated
by the greater number of the MD group completing the
both the 16-week weight loss phase and 24-week weight
maintenance phase. Lack of significant between group
differences in completion rate may have been muted by
the high and equal dietary support given to both groups,
as well as the relatively small study sample size.
While the results of this study are compelling, limita-
tions do exist. The overall drop-out rate of 43.2% for
the MD group after ten months, is a limitation of the
study, though it is consistent with the rates found for
four of the most common diet plans studied for only a
two-month period: Atkins (47%), Ornish (50%), Weight
Watchers (35%), and Zone (35%) [37]. Dietary fatigue,
as a result of using the same or similar meal replace-
ments, could be a factor in the drop-out rate of the MD
group, however, this drop-out rate was similar to a
recent study using MD meal replacements over a com-
p a r a b l et i m ef r a m e[ 8 ] .T h eh i g h e rc o m p l e t i o nr a t ei n
the MD group, although not significant, may have been
affected by meal replacements being provided during
the study, whereas participants in the FB group were
responsible for providing their own food. In addition to
the provision of meal replacements during the study,
the dietitian/participant relationship could have affected
individual results, compliance, and completion of the
study. As stated previously, it was impossible to blind
subjects to the intervention and it is possible being ran-
domized to an undesired group, also affected individual
results, compliance, and completion of the study. Over-
all, the drop-out rate was higher than expected given
the close follow-up with dietitians. Finally, while this
study reports significant findings for many secondary
outcomes (as shown in Tables 2, 3, 4, 5), it was only
powered to detect the primary outcomes of body weight
and body composition.
Conclusions
In conclusion, we found that a meal replacement diet
plan of a fixed macronutrient composition yielded clini-
cally significant weight loss for 93% of obese partici-
pants. This is roughly twice as much as the rate
demonstrated in controlled clinical trials of currently
approved pharmacologic agents for obesity treatment
[28]. Also, the intervention with meal replacements
yielded changes in body composition that favorably
impacted many cardiovascular health outcomes. Our
d a t as u g g e s tt h a tt h em e a lr e p l a c e m e n td i e tp l a ne v a l u -
ated is an effective strategy for producing robust initial
weight loss, and for achieving improvements in a num-
ber of health parameters during weight maintenance,
including inflammation and oxidative stress, two key
factors recently understood to underlie our most com-
mon chronic diseases.
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